Your browser doesn't support javascript.
loading
Variations in primary sclerosing cholangitis across the age spectrum.
Eaton, John E; McCauley, Bryan M; Atkinson, Elizabeth J; Juran, Brian D; Schlicht, Erik M; de Andrade, Mariza; Lazaridis, Konstantinos N.
Afiliação
  • Eaton JE; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota, USA.
  • McCauley BM; Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota, USA.
  • Atkinson EJ; Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota, USA.
  • Juran BD; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota, USA.
  • Schlicht EM; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota, USA.
  • de Andrade M; Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota, USA.
  • Lazaridis KN; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota, USA.
J Gastroenterol Hepatol ; 32(10): 1763-1768, 2017 Oct.
Article em En | MEDLINE | ID: mdl-28245345
BACKGROUND AND AIM: Primary sclerosing cholangitis (PSC) typically develops in middle-age adults. Little is known about phenotypic differences when PSC is diagnosed at various ages. Therefore, we sought to compare the clinical characteristics of a large PSC cohort based on the age when PSC was diagnosed. METHODS: We performed a multicenter retrospective review to compare the features of PSC among those diagnosed between 1-19 (n = 95), 20-59 (n = 662), and 60-79 years (n = 102). RESULTS: Those with an early diagnosis (ED) of PSC were more likely to have small-duct PSC (13%) than those with a middle-age diagnosis (MD) (5%) and late diagnosis (LD) groups (2%), P < 0.01, and appeared to have a decrease risk of hepatobiliary malignancies: ED versus MD: hazard ratio (HR), 0.25; 95% confidence interval (CI) 0.06-1.03, and ED versus LD: HR, 0.07; 95% CI 0.01-0.62. Cholangiocarcinoma was diagnosed in 78 subjects (ED n = 0, MD n = 66, and LD n = 12) and was more likely to be diagnosed within a year after the PSC diagnosis among those found to have PSC late in life: ED 0% (0/95), MD 2% (14/662), and LD 6% (6/102), P = 0.02. Similarly, hepatic decompensation was more common among those with LD-PSC versus younger individuals: LD versus MD: HR, 1.64; 95% CI 0.98-2.70, and LD versus ED: HR, 2.26; 95% CI 1.02-5.05. CONCLUSIONS: Those diagnosed with PSC early in life are more likely to have small-duct PSC and less likely to have disease-related complications. Clinicians should be vigilant for underlying cholangiocarcinoma among those with PSC diagnosed late in life.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colangite Esclerosante Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Screening_studies Limite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colangite Esclerosante Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Screening_studies Limite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article